Pfizer Limited has announced the opening of a special window for investors to re-lodge transfer requests and dematerialize physical securities. The pharmaceutical company published newspaper advertisements in Business Standard (English) and Sakaal (Marathi) on April 8, 2026, informing shareholders about this important regulatory compliance initiative.

SEBI Regulatory Compliance

The special window has been established pursuant to SEBI circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. This regulatory directive aims to facilitate the ease of investment processes for shareholders holding physical securities.

Special Window Details

The one-year window provides investors with an extended opportunity to complete pending transfer and dematerialization processes for their physical share certificates.

Communication and Accessibility

Pfizer Limited has ensured comprehensive communication of this initiative through multiple channels. The company has published the advertisement in both English and regional language newspapers to reach a broader investor base. Additionally, the newspaper advertisement has been uploaded on the company's official website at www.pfizerltd.co.in for easy access by shareholders.

Corporate Compliance

The announcement was made through a formal letter to BSE Limited (Scrip Code: 500680) and The National Stock Exchange of India Ltd. (Scrip Symbol: PFIZER) on April 8, 2026. The communication was signed by Prajeet Nair, Director – Corporate Services & Company Secretary, demonstrating the company's commitment to regulatory compliance and transparent investor communication.

This initiative reflects Pfizer Limited's proactive approach to facilitating investor services and ensuring compliance with evolving regulatory requirements in the Indian securities market.

Pfizer Limited has announced significant changes in its senior management team, informing stock exchanges of two key departures scheduled for 2026. The pharmaceutical company submitted the mandatory disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on March 31, 2026.

Senior Management Departures

The company has reported two distinct changes affecting its senior leadership structure:

Regulatory Compliance

Pfizer Limited has fulfilled its regulatory obligations by submitting the required documentation to both BSE Limited and the National Stock Exchange of India. The company provided Mr. Deepak Rakheja's resignation letter as Annexure A, complying with SEBI Listing Regulations 2015 and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

In his resignation letter dated March 31, 2026, Mr. Rakheja expressed gratitude to the management and colleagues for their support during his tenure with the company. He confirmed his departure effective close of business hours on July 8, 2026, to pursue opportunities outside Pfizer.

Corporate Communication

The disclosure was signed by Prajeet Nair, Director – Corporate Services & Company Secretary, and submitted digitally on March 31, 2026. The company requested stock exchanges to take the information on record, ensuring transparency in corporate governance and compliance with listing requirements.

These management changes represent routine corporate transitions within the pharmaceutical company's organizational structure, with both departures following proper regulatory disclosure procedures.